Darlene Dobkowski, MA | Authors


Daratumumab Combination Therapy Established Standard of Care for Newly Diagnosed Multiple Myeloma

October 04, 2021

A recent presentation during the 18th International Myeloma Workshop focused on updated efficacy and safety data for daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone after nearly 5 years of median follow-up in the phase 3 MAIA study.

Fixed-Duration Ibrutinib/Venetoclax Shows Greater PFS in CLL

June 12, 2021

A fixed duration of ibrutinib plus venetoclax led to a significant progression-free survival benefit over chlorambucil plus obinutuzumab as frontline treatment in patients with chronic lymphocytic leukemia, according to a primary analysis of the phase 3 GLOW study presented at the European Hematology Association 2021 Virtual Congress.

Durable Responses Seen with Cilta-Cel at 18 Months in Relapsed/Refractory Multiple Myeloma

June 08, 2021

Sustained efficacy and durable responses was seen with Ciltacabtagene autoleucel, an investigational B-cell maturation antigen-directed CAR T-cell therapy, in heavily pretreated patients with relapsed/refractory multiple myeloma.